IRON (Disc Medicine) OCF Margin %: 0.00% (As of Mar. 2026)


IRON Disc Medicine Inc IRON
34 GF Score
Price $70.08
! 3 Warning Signs
View Full Analysis

What is Disc Medicine OCF Margin %?

Disc Medicine IRON -0.30% 34 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates IRON with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, Disc Medicine ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Disc Medicine's Cash Flow from Operations for the three months ended in Mar. 2026 was $-62.24 Mil. Disc Medicine's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Disc Medicine's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Disc Medicine's current OCF Yield % is -7.51%.

The historical rank and industry rank for Disc Medicine's OCF Margin % or its related term are showing as below:


IRON's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Disc Medicine OCF Margin % Related Terms

Disc Medicine OCF Margin % Historical Data

* Premium members only.

The historical data trend for Disc Medicine's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Disc Medicine OCF Margin % Chart

Disc Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Disc Medicine Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IRON
34GF Score
Disc Medicine Inc IRON
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Disc Medicine OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Disc Medicine's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-180.393/0
= %

Disc Medicine's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-62.236/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Disc Medicine (IRON) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Disc Medicine and its competitors. According to the industry distribution chart, Disc Medicine ranks #999999 out of 960 companies in the Biotechnology industry.
Is Disc Medicine's OCF Margin % too high?
Disc Medicine's current OCF Margin % is 0.00%. Based on the distribution chart, Disc Medicine ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Disc Medicine has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Disc Medicine's OCF Margin % compare to DFTX and ARQT?
According to the Biotechnology industry distribution chart, Disc Medicine ranks #999999 out of 960 companies for OCF Margin %. This places Disc Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Disc Medicine and its competitors. Disc Medicine's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disc Medicine stock overvalued right now?
Disc Medicine (IRON) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Disc Medicine's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Disc Medicine (IRON), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Disc Medicine Business Description

Address 321 Arsenal Street, Suite 101, Watertown, MA, USA, 02472
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
34GF Score

Get the complete analysis for IRON

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$70.08
Price